SOURCE: Novo Nordisk A/S

March 17, 2008 09:45 ET

Novo Nordisk A/S - Share repurchase programme

BAGSVAERD, DENMARK--(Marketwire - March 17, 2008) - On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Since the announcement as of 10 March 2008, the following transactions have been made under the programme:

                     Number of shares      Average purchase     Transaction
                                                price            value, DKK

Accumulated, last
 announcement            1,407,907                              460,189,198
10 Mar 2008                 50,000              330.1300         16,506,500
11 Mar 2008                 50,000              325.1000         16,255,000
12 Mar 2008                 50,000              324.2900         16,214,500
13 Mar 2008                 50,000              321.6600         16,083,000
14 Mar 2008                 50,000              321.2500         16,062,500
Accumulated, 2008        1,657,907                              541,310,698

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 7,000 B shares. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 26,618,090 treasury shares, corresponding to 4.1% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Stock Exchange Announcement no 16 / 2008

Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • Further information:


    Outside North America:
    Elin K Hansen
    Tel: (+45) 4442 3450
    Email Contact


    Outside North America:
    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Hans Rommer
    Tel: (+45) 4442 4765
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact

    In North America:
    Christian Qvist Frandsen
    Tel: (+1) 609 919 7937
    Email Contact